KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Expenses: 2013-2025

Historic Operating Expenses for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $96.3 million.

  • Xenon Pharmaceuticals' Operating Expenses rose 30.76% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.3 million, marking a year-over-year increase of 36.30%. This contributed to the annual value of $279.3 million for FY2024, which is 30.48% up from last year.
  • Xenon Pharmaceuticals' Operating Expenses amounted to $96.3 million in Q3 2025, which was up 2.24% from $94.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Operating Expenses high stood at $96.3 million for Q3 2025, and its period low was $20.4 million during Q1 2021.
  • In the last 3 years, Xenon Pharmaceuticals' Operating Expenses had a median value of $69.1 million in 2024 and averaged $69.5 million.
  • Data for Xenon Pharmaceuticals' Operating Expenses shows a peak YoY soared of 87.68% (in 2023) over the last 5 years.
  • Xenon Pharmaceuticals' Operating Expenses (Quarterly) stood at $28.6 million in 2021, then spiked by 51.64% to $43.3 million in 2022, then increased by 23.92% to $53.7 million in 2023, then soared by 44.29% to $77.5 million in 2024, then surged by 30.76% to $96.3 million in 2025.
  • Its Operating Expenses stands at $96.3 million for Q3 2025, versus $94.2 million for Q2 2025 and $80.2 million for Q1 2025.